Skip to main content
Caplight Logo









Isabl

Isabl

Private
New York City, New YorkHealthcare & Life Scienceshttps://www.isabl.io/

Last Round

Grant

Mar 8, 2024

Est. Valuation

$2.14M

Total Funding Raised

$6.22M

Company Overview

Isabl is a biotechnology company that has developed a medical diagnosis platform to analyze the entire genome and transcriptome of cancer patients.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Healthcare Analytics, Database Management

Business Model

B2B

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Infrastructure

Keywords

precision medicinebioinformaticswhole genome sequencingWGStranscriptome sequencingWGTSbiomarker discoverygenomic diagnosticsmulti-omicsbioinformatics platformclinical decision supportgenomic data managementpipeline orchestrationcancer genomicsbioinformatics SaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Isabl Comparables

Compare Isabl with similar companies based on industry and business-model similarity.

Isabl comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
BostonGene
77%
OncoDNA
76%
GenomOncology
75%

Isabl Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 8, 2024
SeedMay 18, 2022
GrantApr 1, 2022
AcceleratorApr 3, 2020

Key People

Founding team and executive leadership

Elli Papaemmanuil

Co-Founder And CEO

Founding Team

Isabl Investors

Notable investors and investment history

Isabl investors
InvestorRounds
National Cancer InstituteGrant
Two Sigma VenturesSeed
BoxOne VenturesSeed
Y CombinatorSeed, Accelerator
Evolution VC PartnersSeed
Sand Hill AngelsSeed, Accelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 18, 2022

    $3M round led by Two Sigma Ventures and Deviation Capital.

  • Apr 1, 2022

    $1M grant received from the National Cancer Institute.

Isabl Filings

Explore SEC and related filing metadata, where available.

Isabl filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Isabl's valuation, stock price, and market status.

Is Isabl a public or private company?

Isabl is a private company.

What is the current stock price of Isabl?

Isabl is a private company with no public stock price. No recent secondary market data is available.

How much is Isabl worth (valuation)?

Valuation information for Isabl is not publicly available.

Can I buy Isabl stock?

Isabl shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Isabl's last funding round?

Isabl's most recent funding round was Grant on March 8, 2024.

Who are the main investors in Isabl?

Key investors in Isabl include National Cancer Institute, Two Sigma Ventures.

Will Isabl IPO soon?

No public IPO plans have been announced for Isabl.

How can I track Isabl secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Isabl's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersNew York City, New York
Employee Range7
Year Founded2020
Last FundingMar 8, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?